Boston Scientific Corp (BSX) Stock Price & Analysis
Boston Scientific Corp (BSX) rose 0.53% to USD 48.96 as of June 9, 2026 at 22:38 UTC, according to Nexqual real-time market data.
BSX last closed at USD 48.7; the session ranged USD 48.67–49.86 on volume of 16,229,910 shares. Market capitalization is $72.77B, with a 52-week range of USD 47.17–109.5 (NYQ). Source: Nexqual, June 9, 2026 at 22:38 UTC.
Key Statistics (as of June 9, 2026 at 22:38 UTC)
| Price | USD 48.96 |
|---|---|
| Change | ▲ 0.53% (up) |
| Previous Close | USD 48.7 |
| Open | USD 48.76 |
| Day Range | USD 48.67 – 49.86 |
| 52-Week Range | USD 47.17 – 109.5 |
| Volume | 16,229,910 shares |
| Market Cap | $72.77B |
| Exchange | NYQ |
Technical Analysis (BSX)
Nexqual's technical model rates BSX "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 22:38 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.69 (oversold) |
| vs SMA50 | Below (USD 57.14) |
| MACD | -2.8 (negative) |
Analyst Ratings (BSX)
Wall Street analysts rate BSX "Strong Buy" based on 30 analysts, with a mean price target of USD 78.17 (range USD 55–106), per Nexqual as of June 9, 2026 at 22:38 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 30 |
| Mean Target | USD 78.17 |
| High Target | USD 106 |
| Low Target | USD 55 |
| Buy / Hold / Sell | 27 / 4 / 0 |
Earnings (BSX)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 0.83 |
| Revenue Estimate | $5.38B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.8 vs est 0.79 ▲ beat |
| 2025-12-31 | USD 0.8 vs est 0.78 ▲ beat |
| 2025-09-30 | USD 0.75 vs est 0.71 ▲ beat |
| 2025-06-30 | USD 0.75 vs est 0.73 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:38 UTC.
Financials & Fundamentals (BSX)
| Total Revenue | $20.61B |
|---|---|
| Revenue Growth (YoY) | +11.60% |
| Gross Margin | +68.94% |
| Operating Margin | +20.60% |
| Profit Margin | +17.29% |
| ROE | +14.66% |
| Debt / Equity | 42.25 |
| Current Ratio | 1.9 |
| Total Cash | $1.45B |
| Total Debt | $11.03B |
| Free Cash Flow | $2.81B |
Source: Nexqual, June 9, 2026 at 22:38 UTC.
Financial Health Score (BSX)
Nexqual rates Boston Scientific Corp's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:38 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 69%, operating 21% |
| Balance Sheet | Solid — $1.45B cash vs $11.0B debt |
| Cash Flow | Solid — FCF $2.81B, 14% margin |
| Efficiency | Mixed — ROE 15%, ROA 6.1% |
Ownership (BSX)
| Insider Ownership | +0.23% |
|---|---|
| Institutional Ownership | +95.05% |
| Shares Outstanding | 1.49B |
| Float | 1.48B |
| Short % of Float | +2.12% |
Source: Nexqual, June 9, 2026 at 22:38 UTC.
Leadership (BSX)
Boston Scientific Corp is led by Michael F. Mahoney (age 60), Chairman, President & CEO, per Nexqual as of June 9, 2026 at 22:38 UTC.
| Chairman, President & CEO | Michael F. Mahoney (age 60) |
|---|---|
| Executive VP & CFO | Jonathan R. Monson (age 51) |
| Executive VP & Group President of Cardiovascular | Joseph M. Fitzgerald (age 61) |
| Executive VP and Group President of MedSurg & Asia Pacific | Arthur Crosswell Butcher (age 54) |
| Executive Vice President of Global Operations | Paudie O'Connor (age 57) |
Major Backers & Investors (BSX)
Notable institutional backers of Boston Scientific Corp include FMR, LLC, JPMorgan, Primecap Management Company, according to Nexqual as of June 9, 2026 at 22:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 4.99% |
| JPMorgan | 2.24% |
| Primecap Management Company | 2.19% |
| Shaw D.E. & Co., Inc. | 1.64% |
| Bank of America Corporation | 1.53% |
| Fidelity | 1.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.28% |
| BlackRock | 10.16% |
| State Street | 5.76% |
| Geode Capital | 2.24% |
Source: Nexqual, June 9, 2026 at 22:38 UTC.
From Boston Scientific Corp's Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
- The company operates in two segments, MedSurg and Cardiovascular.
- In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MDT | Medtronic plc. | USD 81.98 | ▲ 0.38% |
| SYK | Stryker Corporation | USD 314.01 | ▲ 2.73% |
| EW | Edwards Lifesciences Corporatio | USD 87.54 | ▲ 1.84% |
| BAX | Baxter International Inc. | USD 20.03 | ▲ 3.35% |
| BDX | Becton, Dickinson and Company | USD 152.04 | ▲ 0.58% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:38 UTC. This page is informational and not investment advice.